Amgen Becomes Early MiSeqDx Adopter for Vectibix CDx; Illumina Plans for Shared 'Onco Panels' | GenomeWeb

Originally published Jan. 17.

Less than five years ago, Amgen was facing criticism from researchers and industry experts for waiting too long to pursue a biomarker strategy to limit the indication for its colorectal cancer drug Vectibix, since in their view, the scientific literature had clearly shown that patients with KRAS mutations wouldn't respond to the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.